Compare Merck & Co., Inc. (MRK) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ProShares UltraPro S&P500 — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while ProShares UltraPro S&P500 trades at $141.53. The key difference: Merck & Co., Inc. pays a 2.73% dividend while ProShares UltraPro S&P500 pays none. Which is the better fit depends on your goals.
| MRK | UPRO | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.52 | $150.93 |
52-Week Low | $77.60 | $89.29 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
UPRO trades at $138.50, down 0.4% on the day, with technical indicators showing a bearish bias as the stock faces resistance near $140-141 levels. The overall technical signal is bearish with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights broader S&P 500 concerns about valuation levels and market concentration in tech stocks, creating headwinds for leveraged ETFs like UPRO.
The outlook for UPRO remains challenged by elevated market valuations and technical resistance. Investment opportunity exists if the S&P 500 breaks through current resistance levels, but risks include continued market volatility and potential mean reversion in tech-heavy indices. The bearish technical setup suggests caution in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
